These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31101074)

  • 1. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
    Zhao D; Klempner SJ; Chao J
    J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
    Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
    Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
    JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
    Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
    Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.
    Nagaraja AK; Kikuchi O; Bass AJ
    Cancer Discov; 2019 Dec; 9(12):1656-1672. PubMed ID: 31727671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
    Maresch J; Schoppmann SF; Thallinger CM; Zielinski CC; Hejna M
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):310-22. PubMed ID: 21783379
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead.
    Stroes CI; van den Ende T; Derks S; van Laarhoven HWM
    Cancer Treat Rev; 2021 Sep; 99():102249. PubMed ID: 34171733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
    Kaur A; Dasanu CA
    Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
    Tabernero J; Shen L; Elimova E; Ku G; Liu T; Shitara K; Lin X; Boyken L; Li H; Grim J; Ajani J
    Future Oncol; 2022 Sep; 18(29):3255-3266. PubMed ID: 36000541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.
    Hicks DG; Whitney-Miller C
    Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):506-8. PubMed ID: 22089490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
    Press MF; Ellis CE; Gagnon RC; Grob TJ; Buyse M; Villalobos I; Liang Z; Wu S; Bang YJ; Qin SK; Chung HC; Xu J; Park JO; Jeziorski K; Afenjar K; Ma Y; Estrada MC; Robinson DM; Scherer SJ; Sauter G; Hecht JR; Slamon DJ
    Mol Cancer Ther; 2017 Jan; 16(1):228-238. PubMed ID: 27811012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First comprehensive guideline released for the assessment of HER2 in patients with GEA.
    Washington MK
    MLO Med Lab Obs; 2017 Mar; 49(3):30-1. PubMed ID: 29924569
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
    Maron SB; Catenacci DVT
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for advanced esophagogastric adenocarcinoma.
    Kordes S; Cats A; Meijer SL; van Laarhoven HW
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted HER2 treatment in advanced gastric cancer.
    Jørgensen JT
    Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
    Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
    J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
    Koltz BR; Hicks DG; Whitney-Miller CL
    Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.